Department of Radiation Oncology, Emory University, Atlanta, Georgia 30322, USA.
Am J Clin Oncol. 2010 Apr;33(2):168-72. doi: 10.1097/COC.0b013e3181a44ebe.
Although specialized (urology/radiotherapy [RT]) databases have been used to measure practice patterns in nonmetastatic prostate cancer, the Surveillance, Epidemiology, and End Results (SEER) registry has not yet been employed for this task in detail. Our objectives were to analyze time trends in the use of surgery and RT and type of RT (external beam RT [EBRT], brachytherapy [Brachy] or combination EBRT + Brachy [Combo]).
Eight lakh twenty-three thousand two hundred ninety-four patients in the SEER public-use registry (1973-2004) were identified. Modality time-trend curves were plotted for the whole group and by (a) grade (well-differentiated [WD], moderately differentiated [MD], and poorly differentiated [PD]) and (b) stage (modified AJCC stage 0-I, stage II, and stage III). A nonparametric (Spearman) test was used to assess correlation of diagnosis year with (a) percentage use of RT and (b) percentage use of EBRT, Brachy, and Combo.
RT use steadily increased from 9.1% in 1973 to 26.0% in 2004 (P < 0.001). Within RT, EBRT use decreased from 99.3% to 59.3% (P < 0.001), Brachy use increased from 0.0% to 29.6% (P < 0.001), and Combo use increased from 0.0% to 11.1% (P < 0.001). Similar time-trend curves to the overall group were observed for all grades and for stage 0 to II patients; stage III time trends were somewhat more static.
Our SEER analysis demonstrated an expected rise in RT use (and relative increase in Brachy) paralleling the rise in evidence for modern EBRT and Brachy efficacy/safety. Within stated limitations, these results can serve as national benchmarks to assess prevailing referral patterns in a given institution or region.
尽管专门的(泌尿科/放疗[RT])数据库已被用于衡量非转移性前列腺癌的实践模式,但 Surveillance, Epidemiology, and End Results(SEER)登记处尚未详细用于此任务。我们的目的是分析手术和 RT 的使用以及 RT 类型(外照射 RT[EBRT]、近距离放射治疗[Brachy]或 EBRT+Brachy 联合[Combo])的时间趋势。
在 SEER 公共使用登记处(1973-2004 年)中确定了 823294 名患者。为整个组和(a)分级(分化良好[WD]、中度分化[MD]和低分化[PD])和(b)分期(改良 AJCC 分期 0-I、分期 II 和分期 III)绘制了方式时间趋势曲线。非参数(Spearman)检验用于评估诊断年份与(a)RT 使用百分比和(b)EBRT、Brachy 和 Combo 使用百分比的相关性。
RT 使用从 1973 年的 9.1%稳步增加到 2004 年的 26.0%(P<0.001)。在 RT 内,EBRT 使用从 99.3%下降到 59.3%(P<0.001),Brachy 使用从 0.0%增加到 29.6%(P<0.001),Combo 使用从 0.0%增加到 11.1%(P<0.001)。所有分级和 0 至 II 期患者的总体组观察到类似的时间趋势曲线;III 期时间趋势则较为稳定。
我们的 SEER 分析表明,随着现代 EBRT 和 Brachy 疗效/安全性证据的增加,RT 使用(以及 Brachy 的相对增加)预计会增加。在规定的限制内,这些结果可以作为国家基准,以评估特定机构或地区的现行转诊模式。